Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN #1302)
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Ixazomib (Primary) ; Bortezomib; Fludarabine; Melphalan
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Therapeutic Use
- 21 Nov 2016 Planned End Date changed from 1 Aug 2022 to 1 Mar 2023.
- 21 Nov 2016 Planned primary completion date changed from 1 Aug 2020 to 1 Mar 2021.
- 21 Nov 2016 Status changed from active, no longer recruiting to recruiting.